Cover Image
Market Research Report

Report Package - 4 for 2: "Drug the Undruggable" Technologies

Published by La Merie Publishing Product code 936691
Published Content info 4 Reports
Delivery time: 1-2 business days
Price
Back to Top
Report Package - 4 for 2: "Drug the Undruggable" Technologies
Published: May 18, 2020 Content info: 4 Reports
Description

This report package includes four full reports for the price of two:

  • Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

This report provides you with a landscape description and analysis of Targeted Protein Degradation (TPD) technologies and of discovery and development of TPD drug candidates from an industry perspective as of May 2020. This report evaluates the industry landscape of targeted protein degradation with novel PROTAC and molecular glue technologies and compounds. The report is based on the identification and description of 20 major biopharmaceutical and 24 technology-focused companies with targeted protein degradation technologies and research and development activities.

  • RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

This report provides you with a landscape description and analysis of discovery and development of small molecules against RNA as a drug target from an industry perspective as of September 2019.

  • Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends

This report brings you up-to-date regarding key technologies

  • for identification and validation of intracellular targets,
  • for generation of T-cell receptors (TCR) and TCR fusion proteins,
  • for discovery of TCR-like antibodies, and
  • for construction of cell-penetrating peptides, proteins and antibodies.
  • TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals

This report published in May 2018 brings you up-to-date regarding key TCR-T players, key TCR-T technologies and product candidates, business models, deals and funding opportunities. The report analyzes the TCR-T pipelines and stakeholders in the field, especially focused and diversified TCR-T companies and their relationship with academia and major pharma/biotech. The report highlights the value of TCR-T assets in terms of partnering economic conditions, acquisition prices and financing rounds.

Table of Contents
Product Code: LMFR0032

Table of Contents

Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: A Landscape Analysis of Companies, Technologies, Targets, Investors and Partners from an Industry Perspective

Abbreviations

1. Executive Summary

2. Introduction & Overview

3. Description and Analysis

  • 3.1. Characterization of Technology Companies
    • 3.1.1. Key Features of Targeted Protein Degradation (TPD) Technologies
    • 3.1.2. E3 Ligases & Linkers
    • 3.1.3. Targets & Target Discovery
    • 3.1.4. Pipeline of Targeted Protein Degraders
    • 3.1.5. Financing & Partnering
  • 3.2. Major Pharmaceutical Companies and Targeted Protein Degradation
    • 3.2.1. TPD Drug Candidates in Development by Major Pharma Companies
    • 3.2.2. Major Pharma's Internal TPD Activities
      • 3.2.2.1 Resistance to TPD
      • 3.2.2.2 Target Proteins
      • 3.2.2.3 Discovery Approaches
      • 3.2.2.4 Ligase Selection & Ligase Binderss
      • 3.2.2.5 Safety
      • 3.2.2.6 Antibody-based Targeted Protein Degraders
      • 3.2.2.7 PROTAC vs Molecular Glue Targeted Protein Degraders

4. Profiles of TPD Technology Companies

  • 4.1. Amphista Therapeutics
  • 4.2. Arvinas
  • 4.3. BiotheryX
  • 4.4. C4 Therapeutics
  • 4.5. Captor Therapeutics
  • 4.6. Cedilla Therapeutics
  • 4.7. Cullgen
  • 4.8. Dialectic Therapeutics
  • 4.9. FIMECS
  • 4.10. Hinova Pharmaceuticals
  • 4.11. Kronos Bio
  • 4.12. Kymera Therapeutics
  • 4.13. Lycia Therapeutics
  • 4.14. Monte Rosa Therapeutics
  • 4.15. Nurix Therapeutics
  • 4.16. Oncopia Therapeutics
  • 4.17. Orionis Biosciences
  • 4.18. Pin Therapeutics
  • 4.19. Plexium
  • 4.20. PolyProx Therapeutics
  • 4.21. Sitryx Therapeutics
  • 4.22. Trilo Therapeutics
  • 4.23. Ubiquigent
  • 4.24. Ubix Therapeutics

5. Profiles of Major Pharmaceutical Companies with Stakes in TPD

  • 5.1. AbbVie
  • 5.2. Amgen
  • 5.3. AstraZeneca
  • 5.4. Bayer
  • 5.5. Biogen
  • 5.6. Bristol-Myers Squibb (& Celgene)
  • 5.7. Boehringer Ingelheim
  • 5.8. Calico Life Sciences
  • 5.9. Eisai
  • 5.10. Eli Lilly
  • 5.11. Gilead Sciences
  • 5.12. GlaxoSmithKline
  • 5.13. Janssen (Johnson & Johnson)
  • 5.14. LEO Pharma
  • 5.15. Merck
  • 5.16. Novartis
  • 5.17. Pfizer
  • 5.18. Roche
  • 5.19. Sanofi
  • 5.20. Vertex Pharmaceuticals

6. Profiles of TPD Technologies

  • 6.1. PROTAC Protein Degradation (Arvinas)
  • 6.2. Daedalus Technology Platform (C4 Therapeutics)
  • 6.3. DELPHe Platform (Plexium)
  • 6.4. Pegasus Technology (Kymera)
  • 6.5. Protein Degradation by Intrinsic Pathways (Cedilla Therapeutics)
  • 6.6. Protein Hemostatic Modulators (BioTheryX)
  • 6.7. Targeted Protein Modulation (Nurix Therapeutics)
  • 6.8. uSMITE Technology (Cullgen)

7. Profiles of Drug Candidates

  • 7.1. ARV-110
  • 7.2. ARV-471
  • 7.3. Avadomide
  • 7.4. CC-90009
  • 7.5. CC-92480
  • 7.6. DT2216
  • 7.7. Iberdomide
  • 7.8. KYM-001
  • 7.9. KYM-003
  • 7.10. NRX0492

8. References

List of Tables

  • Table 1: Overview of Technology Companies -- Geography, Foundation & Size
  • Table 2: Overview of Technology Companies -- TPD Technology Characterization
  • Table 3: Overview of Technology Companies -- Technology, Source & Partnering
  • Table 4: Overview of Technology Companies -- Funding, Pipeline & R&D Phase
  • Table 5: Targeted Protein Degradation Technologies and their Key Features
  • Table 6: Ligases Targeted by Protein Degradation Technology Companies
  • Table 7: Protein Targets Pursued by TPD Technology Companies
  • Table 8: Target Identification Technologies of TPD Technology Companies
  • Table 9: Pipeline of Advanced PROTAC Molecules from TPD Technology Companies
  • Table 10: Sources of Financing for TPD Technology Companies
  • Table 11: Investors of TPD Technology Companies
  • Table 12: Partnering Terms of Agreements between TPD Technology Companies and Major Pharmaceutical Companies
  • Table 13: Major Pharmaceutical Companies and Their Stakes in TPD
  • Table 14: Advanced Molecular Glue-like TPD Molecules
  • Table 15: In-House TPD Activities of Major Pharma Companies
  • Table 16: Protein Degradation Approaches of Celgene (BMS)

RNA-Targeted Small Molecules 2019: A Landscape Analysis of Companies, Technologies, Targets, Investors and Partners from an Industry Perspective

1. Executive Summary

2. Introduction & Overview

3. mRNA Translation Regulation by Small Molecules

  • 3.1. Overview
    • 3.1.1. Companies
    • 3.1.2. Technologies and Targets
    • 3.1.3. Preclinical and Clinical Experience
    • 3.1.4. Partnering and Financing
    • 3.1.5. Comparative Assessment
  • 3.2. Company Profiles
    • 3.2.1. Anima Biotech
    • 3.2.2. eFFECTOR Therapeutics
    • 3.2.3. Eloxx Pharmaceuticals
  • 3.3. Selected Technology Profile
    • 3.3.1. Translation Control Therapeutics Platform
  • 3.4. Drug and Drug Candidate Profiles
    • 3.4.1. BAY 1143269
    • 3.4.2. eFT226
    • 3.4.3. eIF4E Inhibitors
    • 3.4.4. ELX-02
    • 3.4.5. Tomivosertib
    • 3.4.6. Translarna

4. RNA Splicing Modification by Small Molecules

  • 4.1. Overview
    • 4.1.1. Companies
    • 4.1.2. Technologies and Targets
    • 4.1.3. Preclinical and Clinical Experience
    • 4.1.4. Partnering and Financing
    • 4.1.5. Comparative Assessment
  • 4.2. Company Profiles
    • 4.2.1. H3 Biomedicine
    • 4.2.2. Panorama Medicine
    • 4.2.3. PTC Therapeutics
    • 4.2.4. Skyhawk Therapeutics
  • 4.3. Selected Technology Profile
    • 4.3.1. RNA Splicing Platform
  • 4.4. Drug Candidate Profiles
    • 4.4.1. Branaplam
    • 4.4.2. E7107
    • 4.4.3. H3B-8800
    • 4.4.4. PTC258
    • 4.4.5. Risdiplam

5. Direct RNA Targeting by Small Molecules

  • 5.1. Overview
    • 5.1.1. Companies
    • 5.1.2. Technologies
    • 5.1.3. Targets and Indications
    • 5.1.4. Partnering and Financing
    • 5.1.5. Comparative Assessment
  • 5.2. Companies
    • 5.2.1. Arrakis Therapeutics
    • 5.2.2. Expansion Therapeutics
    • 5.2.3. Novation Pharmaceuticals
    • 5.2.4. Nymirum
    • 5.2.5. Ribometrix
    • 5.2.6. Saverna Therapeutics
    • 5.2.7. Target RNA

6. Indirect RNA-Targeted (Epitranscriptomic) Small Molecules

  • 6.1. Overview
    • 6.1.1. Companies
    • 6.1.2. Technologies
    • 6.1.3. Targets and Indications
    • 6.1.4. Partnering and Financing
    • 6.1.5. Comparative Assessment
  • 6.2. Company Profiles
    • 6.2.1. AC Immune
    • 6.2.2. Accent Therapeutics
    • 6.2.3. EPICS Therapeutics
    • 6.2.4. Gotham Therapeutics
    • 6.2.5. ImStar Therapeutics
    • 6.2.6. STORM Therapeutics
    • 6.2.7. Twentyeight-Seven Therapeutics

7. Major Pharmaceutical Companies as Stakeholders in RNA-Targeted Small Molecule R&D

  • 7.1. Overview
  • 7.2. Companies
    • 7.2.1. Biogen
    • 7.2.2. Boehringer Ingelheim
    • 7.2.3. Bristol-Myers Squibb
    • 7.2.4. Celgene
    • 7.2.5. Eli Lilly
    • 7.2.6. Merck
    • 7.2.7. Novartis
    • 7.2.8. Pfizer
    • 7.2.9. Roche
    • 7.2.10 Takeda Pharmaceutical Co
    • 7.2.11 UCB

8. Outlook and Perspectives

9. References

10. Addendda

Addendum 1: Small Molecule mRNA Translation Regulators

Addendum 2: Small Molecule RNA Splicing Modifiers

Addendum 3: Direct RNA-Targeted Small Molecules

Addendum 4: Indirect RNA-Targeted Small Molecules (Epitranscriptomics)

Tables

  • Table 1: Overview of Small Molecule Translation Regulator Companies
  • Table 2: Key Features of Technologies to Discover Small Molecule mRNA Translation Regulators
  • Table 3: Targets of Small Molecule mRNA Translation Regulator R&D Programs
  • Table 4: Profiles for Selected Small Molecule mRNA Translation Regulators
  • Table 5: Financing of Small Molecule RNA Translation Regulator Companies by Investors and Collaboration Partners
  • Table 6: Comparative Assessment of Small Molecule mRNA Translation Regulator Companies
  • Table 7: Overview of Companies with Small Molecule RNA Splicing Modifiers
  • Table 8: Key Features of Technologies to Discover Small Molecule RNA Splicing Modifiers
  • Table 9: Targets/Indications of Small Molecule RNA Splicing Modifier R&D Programs
  • Table 10: Profiles for Selected Small Molecule mRNA Translation Regulators
  • Table 11: Financing of RNA Splicing Modifier Companies by Investors and Collaboration Partners
  • Table 12: Comparative Assessment of Small Molecule RNA Splicing Modifier Companies
  • Table 13: Skyhawk Therapeutics' Strategic Collaborations with Major Biopharmaceutical Companies for mRNA Splicing Modifiers Discovered by SkySTAR Technology
  • Table 14: Overview of Companies with Direct RNA-Targeted Small Molecules
  • Table 15: Key Features of Technologies to Discover Direct RNA-Targeted Small Molecules
  • Table 16: Targets/Indications of Direct RNA-Targeted Small Molecule R&D Programs
  • Table 17: Financing of Direct RNA-Targeted Small Molecule Companies by Investors and Collaboration Partners
  • Table 18: Comparative Assessment of Direct RNA-Targeted Small Molecule Companies
  • Table 19: Overview of Companies with Epitranscriptomic Small Molecule Modulators
  • Table 20: Key Features of Technologies to Discover Epitranscriptomic Small Molecule Modulators
  • Table 21: Targets/Indications of Epitranscriptomic Small Molecule Modulator R&D Programs
  • Table 22: Financing of Epitranscriptomic Small Molecule Modulators Companies by Investors and Collaboration Partners
  • Table 23: Comparative Assessment of Epitranscriptomic Small Molecule Modulator Companies
  • Table 24: Major Pharmaceutical Companies as Stakeholders in RNA-Targeted Small Molecule R&D
  • Table 25: Comparison of Four Approaches in RNA-Targeted Small Molecule R&D

TCR Engineered T-Cell Therapy 2018: An Industry Analysis of Technologies, Pipelines, Stakeholders & Deals

1. Executive Summary

2. Introduction, Overview & Background

3. Technologies

  • 3.1. Overview & Discussion
    • 3.1.1. Technologies for Discovery of Antigens for TCRs
    • 3.1.2. Technologies for Discovery of TCRs
    • 3.1.3. Allogeneic T-Cell Technologies
    • 3.1.4. Technologies for Next Generation TCR T-Cells
  • 3.2. Technologies for Discovery of Targets for TCRs
    • 3.2.1. XPRESIDENT
    • 3.2.2. Target Selection for SPEAR T-Cells
    • 3.2.3. Phosphopeptide Library
    • 3.2.4. HTS Platform for Neoantigen Identification
    • 3.2.5. pMHC Target Discovery
    • 3.2.6. EpiTarget Platform
    • 3.2.7. Neoantigen Prediction
  • 3.3. Technologies for TCR Discovery
    • 3.3.1. SPEAR T-Cell Technology
    • 3.3.2. High-Throughput Identification of TUMAP-Restriced TCRs & ActEngine
    • 3.3.3. Single Cell Sequencing Platform
    • 3.3.4. TCR-GENErator
    • 3.3.5. HTS TCR Discovery and Sleeping-Beauty Expression System
    • 3.3.6. Natural, High Affinity TCRs (Bellicum)
    • 3.3.7. High-throughput cloning and characterisation of naturally selected TCRs
    • 3.3.8. Natural TCR Library
    • 3.3.9. Natural TCRs from Vaccinated Patients
    • 3.3.10. T-Rx Mammalian TCR Display
    • 3.3.11. VelociT for T-Cell Receptor Discovery
    • 3.3.12. Combinatorial TCR Exchange (CTE)
    • 3.3.13. Immune Repertoire Capture
    • 3.3.14. E-ALPHA Phage Display
    • 3.3.15. TCRL Antibodies
    • 3.3.16. ACTolog
    • 3.3.17. NEO-STIM
  • 3.4. TCR Engineered Allogeneic T-Cells
    • 3.4.1. ACTallo
    • 3.4.2. universal Immune Cell Therapies (uICT)
    • 3.4.3. GammaDelta T-Cells
    • 3.4.4. Universal Donor Stem Cells
    • 3.4.5. ATO Allogeneic T-Cells
  • 3.5. Next Generation Technologies to Improve Safety & Efficacy
    • 3.5.1. ARTEMIS Technology
    • 3.5.2. CID Technology Platform
    • 3.5.3. Custom Cell Engineering Technologies synNotch and Throttle
    • 3.5.4. DEACT Technology
    • 3.5.5. Dominant TCR Technology
    • 3.5.6. RetroNectin and siTCR Vector Technologies
    • 3.5.7. Stem-to-T-Cell Technology
    • 3.5.8. Transmembrane Immunomodulatory Protein (TIP) Technology

4. Pipeline

  • 4.1. Overview & Discussion
    • 4.1.1. Proof-of-concept
    • 4.1.2. Target Selection
    • 4.1.3. T-Cell Sources & Subtypes
    • 4.1.4. Use of Switches & Next Generation Constructs
  • 4.2. Profiles of MAGE-A Specific TCR T-Cells
    • 4.2.1. KITE-718
    • 4.2.2. MAGE-A4c1032 T
    • 4.2.3. MAGE-A10c796 T
    • 4.2.4. TBI-1201
  • 4.3. Profiles of NY-ESO-1 Specific TCR T-Cells
    • 4.3.1. GSK3377794
    • 4.3.2. NYCE T Cells
    • 4.3.3. TBI-1301
  • 4.4. Profiles of AFP Specific TCR T-Cells
    • 4.4.1. AFPc332 T
    • 4.4.2. ET1402L1 CAR T-Cells
  • 4.5. Profiles of PRAME Specific TCR T-Cells
    • 4.5.1. BPX-701
    • 4.5.2. MDG1011
    • 4.5.3. Dual Switch PRAME TCR T-Cells
  • 4.6. Profiles of WT1 Specitic TCR T-Cells
    • 4.6.1. CMD-602
    • 4.6.2. JTCR016
    • 4.6.3. WT1-Specific Transgenic T-Cells
  • 4.7. Profiles of Other Target Specific TCR T-Cells
    • 4.7.1. IMA201
    • 4.7.2. KITE-439
    • 4.7.3. LTC-H1
    • 4.7.4. TC-210
    • 4.7.5. ZI-H04
    • 4.7.6. ZI-T01
  • 4.8. Profiles of Neoantigen Specific TCR T-Cells
    • 4.8.1. IMA101
    • 4.8.2. NEO-PTC-01

5. Manufacturing

6. Companies

  • 6.1. Company Overview & Discussion
    • 6.1.1. Pure Play TCR T-Cell Companies
    • 6.1.2. Diversified Companies with TCR-T Activities
  • 6.2. Pure Play TCR T-Cell Companies
    • 6.2.1. Adaptimmune Therapeutics
    • 6.2.2. Gadeta
    • 6.2.3. Immatics US
    • 6.2.4. Lion TCR
    • 6.2.5. Tactiva Therapeutics
    • 6.2.6. Zelluna Immunotherapies
    • 6.2.7. TCR2 Therapeutics
  • 6.3. Profiles of Diversified Companies with TCR-T Activities
    • 6.3.1. Adicet Bio
    • 6.3.2. AgenTus Therapeutics
    • 6.3.3. Bellicum Pharmaceuticals
    • 6.3.4. BioNTech
    • 6.3.5. Bluebird bio
    • 6.3.6. Cell Medica
    • 6.3.7. Eureka Therapeutics
    • 6.3.8. GlaxoSmithKline
    • 6.3.9. Intellia Therapeutics
    • 6.3.10. Juno, a Celgene Company
    • 6.3.11. Kite, a Gilead Company
    • 6.3.12. Medigene
    • 6.3.13. Neon Therapeutics
    • 6.3.14. Regeneron Pharmaceuticals
    • 6.3.15. Takara Bio
    • 6.3.16. TC BioPharm
    • 6.3.17. Tmunity Therapeutics
    • 6.3.18. ZIOPHARM Oncology
  • 6.4. Other Companies with TCR-T Activities
    • 6.4.1. Alpine Immune Sciences
    • 6.4.2. Atreca
    • 6.4.3. ImmunoCellular Therapeutics

7. Business Development & Financing

  • 7.1. Role of academia for the TCR-T industry
  • 7.2. Role of Big Pharma & Biotech for TCR-T
  • 7.3. Technology In-Licensing Deals
  • 7.4. Collaborative Arrangements
  • 7.5. Acquisitions of Companies and Assets
  • 7.6. Financing of TCR-T Companies

8. Outlook & Perspectives

9. References

List of Tables

  • Table 1: Overview of Corporate Technologies to Discover pMHC Targets for TCRs
  • Table 2: Overview of Corporate Technologies to Discover Therapeutic TCRs
  • Table 3: Overview of Corporate Technologies of TCR-Engineered Allogeneic T-Cells
  • Table 4: Overview of Corporate Technologies to Improve Safety & Efficacy of TCR T-Cells
  • Table 5: Overview of TCR T-Cell Constructs in Development
  • Table 6: Overview of Company Solutions for Manufacturing of Vector & Cells
  • Table 7: Overview of in-house Company Manufacturing Solutions
  • Table 8: Overview of Company Choices of CMO
  • Table 9: Overview of Company Manufacturing Collaborations with Academia/Hospitals
  • Table 10: Overview of TCR T-Cell Company Profiles
  • Table 11: Overview of Profiles of Pure Play TCR-T Companies
  • Table 12: Overview of Profiles of Diversified Companies with TCR-T Activities
  • Table 13: Adaptimmune's Pipeline of SPEAR T-Cells
  • Table 14: TCR T-cell Pipeline of Lion TCR
  • Table 15: TCR2 Therapeutics' TRuC-T Cell Pipeline
  • Table 16: TCR T-Cell Pipeline of Zelluna Immunotherapy
  • Table 17: Bellicum Pharmaceuticals' Pipeline
  • Table 18: Cell Medica's Pipeline
  • Table 19: Overview of Kite Pharma's Access to Technologies with Focus on TCR
  • Table 20: NCI Programs of TCR T-Cells under CRADA with Kite
  • Table 21: TC BioPharm's Pipeline of γδ T-cell programs
  • Table 22: Clinical Pipeline of Tmunity Therapeutics
  • Table 23: Technology Spin-Out from Academia
  • Table 24: Deals with Major Pharma & Biotech
  • Table 25: Technology In-Licensing from Pharma & Biotech
  • Table 26: Collaborations & Joint Ventures
  • Table 27: Acquisitions
  • Table 28: Financing Sources of Pure Play TCR-T Companies
  • Table 29: Financing Sources of Selected Diversified Companies with TCR-T Activities

Intracellular Targets Made Druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: An Industry Analysis of Technologies, Stakeholders, Deals & Trends

1. Executive Summary

2. Introduction & Overview

3. Background

4. Technology Profiles

  • 4.1. Overview & Discussion
    • 4.1.1. Intracellular Target Discovery
    • 4.1.2. TCR Discovery Technologies
    • 4.1.3. Generation of TCR-like Antibodies
    • 4.1.4. Generation of TCR Fusion Proteins against Intracellular Targets
    • 4.1.5. Generation of Cell Penetrating Biologics against Intracellular Targets
  • 4.2. Technologies for Discovery of Intracellular Targets
    • 4.2.1. XPRESIDENT
    • 4.2.2. Targets for TCRs (Immunocore)
    • 4.2.3. Phosphopeptide Library
    • 4.2.4. HTS Platform for Neoantigen Identification
    • 4.2.5. ECLIPSE Platform
    • 4.2.6. EpiTarget Platform
    • 4.2.7. Soluble HLA (sHLA) Molecules
    • 4.2.8. Phagemers & SSIp display
    • 4.2.9. Peptide/MHC Complexes
    • 4.2.10 TCR Target Discovery
  • 4.3. Technologies for Discovery of TCRs
    • 4.3.1. Naturally Selected TCRs
    • 4.3.2. TCRs by ImmTAC Technology
    • 4.3.3. HTS for TUMAP-Restricted TCRs
    • 4.3.4. Natural TCR Library
    • 4.3.5. Sleeping-Beauty Expression System
    • 4.3.6. TCR-GENerator
    • 4.3.7. T-Rx Mammalian TCR Display
    • 4.3.8. Single Cell Sequencing Platform
    • 4.3.9. Immune Repertoire Capture
    • 4.3.10 Combinatorial TCR Exchange (CTE)
    • 4.3.11 VelociT for T-Cell Receptor Discovery
  • 4.4. Technologies for Generation of TCRL Antibodies
    • 4.4.1. TandAb
    • 4.4.2. BiTE
    • 4.4.3. E-Alpha Phage Display
    • 4.4.4. HuTARG Protein Engineering
    • 4.4.5. MAR & TriTE
    • 4.4.6. TCRL Antibodies
    • 4.4.7. TCRm Antibodies
    • 4.4.8. Ylanthia Fab library
    • 4.4.9. TCRL ADCs
  • 4.5. Technologies for Generation of TCR Fusion Proteins
    • 4.5.1. ImmTAC
    • 4.5.2. TCR Bispecifics
    • 4.5.3. STAR
  • 4.6. Technologies for Generation of Cell Penetrating Biologics
    • 4.6.1. Cell-Penetrating alpha Bodies
    • 4.6.2. Anti-DNA Autoantibodies
    • 4.6.3. Cell Penetrating Mini Proteins (CPMP)
    • 4.6.4. Feldan Shuttle
    • 4.6.5. Shark VNARs
    • 4.6.6. iMab
    • 4.6.7. iTABs
    • 4.6.8. Stapled Peptides
    • 4.6.9. Single Domain Antibodies

5. Pipeline Analysis and Product Profiles

  • 5.1. Overview Product Profiles and Pipeline Discussion
  • 5.2. Profiles of Selected TCRL Antibodies & TCR Fusion Proteins
    • 5.2.1. IMCgp100
    • 5.2.2. ALT-801
    • 5.2.3. H8F4
    • 5.2.4. MMP1-003 TandAb
    • 5.2.5. ESK1 & ESKM
    • 5.2.6. RL1B
  • 5.3. Profiles of Selected Cell Penetrating Peptides, Proteins & Antibodies
    • 5.3.1. ALRN-6924
    • 5.3.2. Anti-Mcl-1 CPAB
    • 5.3.3. PAT-DX1 & Other Deoxymabs
    • 5.3.4. RT11-i
    • 5.3.5. SBT-100

6. Stakeholder Analysis & Company Profiles

  • 6.1. Stakeholder Analysis and Overview of Company Profiles
  • 6.2. Profiles of Companies with Target Discovery and TCR Fusion Protein Technologies
    • 6.2.1. Agenus
    • 6.2.2. Atreca
    • 6.2.3. Immatics Biotechnologies
    • 6.2.4. Immunocore
    • 6.2.5. Regeneron Pharmaceuticals
  • 6.3. Profiles of Companies with Target Discovery and TCR-Like Antibody Technologies
    • 6.3.1. AbeXXa
    • 6.3.2. Adicet Bio
    • 6.3.3. MD Anderson Cancer Center
    • 6.3.4. Pure MHC
  • 6.4. Profiles of Companies with TCR Fusion Protein and/or TCRL Antibody Technologies
    • 6.4.1. Affimed Therapeutics
    • 6.4.2. NantCell (Altor Bioscience)
    • 6.4.3. Eureka Therapeutics
    • 6.4.4. Innovative Targeting Solutions (ITS)
    • 6.4.5. Morphosys
    • 6.4.6. Receptor Logic (now Pure MHC)
    • 6.4.7. Timmune Biotech
  • 6.5. Profiles of Companies with TCR Discovery Technologies only used for T-Cell Therapy
    • 6.5.1. BioNTech
    • 6.5.2. Gadeta
    • 6.5.3. Gilead Sciences (Kite Pharma)
    • 6.5.4. Juno Therapeutics
    • 6.5.5. Medigene
    • 6.5.6. ZIOPHARM Oncology
  • 6.6. Profiles of Companies with Cell Penetrating (CP) Peptide, Protein or Antibody Technologies
    • 6.6.1. Aileron Therapeutics
    • 6.6.2. Complix
    • 6.6.3. Elasmogen
    • 6.6.4. Feldan Therapeutics
    • 6.6.5. Fog Pharmaceuticals
    • 6.6.6. Orum Pharmaceuticals
    • 6.6.7. Patrys
    • 6.6.8. Singh Biotechnology
    • 6.6.9. Sorrento Therapeutics & LA Cell
  • 6.7. Profiles of Big Pharma & Biotech Companies Active in the Intracellular Target and TCR & Cell Penetrating Biologics Field
    • 6.7.1. AbbVie
    • 6.7.2. Amgen
    • 6.7.3. Astellas Pharma
    • 6.7.4. AstraZeneca
    • 6.7.5. Boehringer Ingelheim
    • 6.7.6. Eli Lilly
    • 6.7.7. GlaxoSmith-Kline
    • 6.7.8. Janssen Biotech
    • 6.7.9. Merck
    • 6.7.10 Novartis
    • 6.7.11 Roche
  • 6.8. Profiles of Other Companies with Stakes in the Field of Intracellular Targets and TCR & Cell Penetrating Biologics
    • 6.8.1. Nextera
    • 6.8.2. Xencor
    • 6.8.3. Zymeworks

7. Deals & Financing

  • 7.1. Partnering Deals between Big Pharma and Technology Companies
  • 7.2. Acquisitions of Technology Companies
  • 7.3. Collaboration and Licensing Deals between Technology Companies
  • 7.4. Financing Sources of Technology Companies

8. Trends & Outlook

10. . References

Tables in the report

  • Overview of Corporate Technologies to Discover Intracellular Targets for TCRs
  • Overview of Corporate Technologies to Discover Therapeutic TCRs
  • Overview of Technologies for Generation of TCRL Antibodies against Intracellular Targets
  • Overview of Technologies for Generation of TCR Fusion Proteins against Intracellular Targets
  • Overview of Technologies for Generation of Cell Penetrating Biologics against Intracellular Targets
  • Affinity Enhancement of TCRs by Immunocore technology
  • Examples of Direct Identification and Confirmation of Class I MHC-Peptide Epitopes on Cells with T-Cell Receptor Mimic Antibodies
  • Profiles of Selected TCRL Antibodies & TCR Fusion Proteins
  • Profiles of Selected Cell Penetrating Peptides, Proteins & Antibodies
  • Clinical Studies with IMCgp100
  • Profiles of Companies with Target Discovery and TCR Fusion Protein Technologies
  • Profiles of Companies with Target Discovery and TCR-Like Antibody Technologies
  • Profiles of Companies with TCR Fusion Protein and/or TCRL Antibody Technologies
  • Profiles of Companies with TCR Discovery Technologies only used for T-Cell Therapy
  • Profiles of Companies with Cell Penetrating (CP) Peptide, Protein or Antibody Technologies
  • Profiles of Big Pharma & Biotech Companies Active in the Intracellular Target and TCR & Cell Penetrating Biologics Field
  • Profiles of Other Companies with Stakes in the Field of Intracellular Targets and TCR & Cell Penetrating Biologics
  • Antibody-based immunotherapeutics against pMHCs* discovered by immatics' XPRESIDENT technology
  • Immunocore's Proprietary and Partnered Pipeline of TCR Fusion Proteins
  • Goals and Terms of Immunocore's Partnering Deals for ImmTAC Technology
  • Innovative Targeting Solutions and Drug Candidates from HuTARG Platform
  • Examples of Direct Identification and Confirmation of Class I MHC-Peptide Epitopes on Cells with T-Cell Receptor Mimic Antibodies
  • Pipeline sdAbs from Singh Biotechnology
  • Collaboration and Licensing Agreements between Big Pharma/Biotech and Technology Companies for Intracellular Targets and Therapeutic Biologics
  • Acquisition of Technology Companies in the Field
  • Collaboration and Licensing Agreements between Technology Companies
  • Financing Sources of Technology Companies in the Field

Companies mentioned in the report:

  • AbbVie
  • AbeXXa Biologics
  • Adicet Bio (Applied Immune Technologies)
  • Affimed Therapeutics
  • Agenus
  • Aileron Therapeutics
  • Amgen
  • Astellas Pharma
  • AstraZeneca
  • Atreca
  • BioNTech
  • Boehringer Ingelheim
  • Complix
  • Elasmogen
  • Eli Lilly
  • Eureka Therapeutics
  • Feldan Therapeutics
  • Fog Pharmaceuticals
  • Gadeta
  • Gilead Sciences (Kite Pharma)
  • GlaxoSmith-Kline
  • Immatics Biotechnologies
  • Immunocore
  • Innovative Targeting Solutions (ITS)
  • Janssen Biotech
  • Juno Therapeutics
  • MD Anderson Cancer Center
  • Medigene
  • Merck
  • Morphosys
  • NantCell (Altor Bioscience)
  • Nextera
  • Novartis
  • Orum Pharmaceuticals
  • Patrys
  • Pure MHC
  • Pure MHC
  • Receptor Logic (now Pure MHC)
  • Regeneron Pharmaceuticals
  • Roche
  • Singh Biotechnology
  • Sorrento Therapeutics & LA Cell
  • Timmune Biotech
  • Xencor
  • ZIOPHARM Oncology
  • Zymeworks
Back to Top